Introduction
Naked plasmid DNA injected into muscle can be taken up by skeletal myocytes adjacent to the site of injection and expressed for up to 19 months. 1 The prospect of using intramuscular injection of naked DNA has obvious advantages over myoblast transplantation and intramuscular injection of recombinant viral vectors. The muscle can serve as a depot of DNA that may be used to correct myopathies, such as Duchenne's muscular dystrophy, and for local secretion of angiogenic, neurotrophic and other growth factors. [2] [3] [4] [5] [6] [7] Intramuscular gene expression can be also used to induce humoral and cell-mediated immune response against infectious diseases and cancer. 8, 9 Despite obvious advantages, potential clinical usefulness of naked DNA is limited. A relatively low level of gene expression achievable with naked DNA is often insufficient to ensure a therapeutic effect. Furthermore, gene expression cannot be enhanced above a certain limit by increasing the dose of naked DNA ('dose-ceiling' effect). A highly variable level of gene expression is also among the problems. 10, 11 Thus, although the use of naked DNA is of high potential, new delivery systems that might help to resolve the above listed problems are highly desirable. Until now, no enhancement in intra-efficacy and its optimal dose was 500-fold lower. Experiments with ␤-galactosidase using X-gal staining suggested that SP1017 considerably increased plasmid DNA diffusion through the tissue. SP1017 also improved expression of the erythropoietin gene leading to an increase in its systemic level and hematocrits. Previous toxicity studies have suggested that SP1017 has over a 1000-fold safety margin. Poloxamers used in SP1017 are listed in the US Pharmacopeia as inactive excipients and are widely used in a variety of clinical applications. We believe that the described system constitutes a simple and efficient gene transfer method to achieve local or systemic production of therapeutic proteins. Gene Therapy (2000) 7, 986-991. muscular gene expression has been reported with nonviral cationic systems. Recently, Mumper and coworkers 12 described a non-ionic polymer carrier, polyvinyl pyrrolidone (PVP), that improves plasmid delivery to rat muscle. Another non-ionic system, a matrix of poly(lactide-co-glycolide), has been recently shown to improve the delivery of plasmid DNA when injected subcutaneously. 13 However, both these systems require high DNA doses to reveal their potentiating effects, which may induce undesirable immune reactions due to a considerable immunomodulating activity of DNA.
14,15 Furthermore, both PVP and poly(lactide-co-glycolide) have to be administered at high concentrations, which may also cause additional side-effects. Electroporation, another approach to increase plasmid DNA transfer to the muscle tissue, gains more and more popularity. However, some problems limit its wide application, such as the need for surgery, risks of extensive and irreversible muscle damage and the use of potent muscle cell regenerating agents, eg cardiotoxin and bupivacain. [16] [17] [18] During the present study, we have found that the combination of two poloxamers (pluronics L61 and F127) significantly increases gene expression in skeletal muscle. In this report, we also demonstrate that the increase in gene expression obtained with SP1017 results in higher physiological response induced by a therapeutic gene, erythropoietin.
Results
The SP1017 carrier The SP1017 carrier system that we used in this study is composed of two poly(ethylene oxide)-poly(propylene oxide) block copolymers of the following general formula:
where y = 31, x = z = 4.5 for pluronic L61, and y = 65.2, x = z = 200.4 for pluronic F127.
Previous studies have demonstrated that these compounds can significantly potentiate cellular uptake and increase both in vitro and in vivo performance of a variety of pharmaceutical agents, including anticancer cytotoxics, peptides and proteins and DNA complexed with polycationic carriers. [19] [20] [21] We have previously established that a combination of pluronics L61 and F127 constitutes an effective carrier system, SP1017, which has high thermodynamic stability and low toxicity. 22 Effect of SP1017 on luciferase gene expression in muscle To evaluate the ability of SP1017 to increase gene expression in muscle, 5 g of plasmid DNA encoding luciferase (pCMV-Luc) were formulated with 50 l of the SP1017 carrier solution (pCMV-Luc/SP1017) at various concentrations and injected into bilateral tibialis anterior muscles of 6-to 8-week-old female C57BL/6 mice. The muscles were harvested 24 h after injection, and the luciferase activity was assayed. The results obtained ( Figure 1a ) demonstrated that at low concentrations, SP1017 increased gene expression in a dose-dependent manner. At higher concentrations of SP1017 in the dosing solution (above 0.01% w/v), the efficacy of gene expression declined. Under the optimal conditions (SP1017 concentration of 0.01% w/v), the expression efficacy was found to be up to 10-fold higher than that of naked DNA. Similar results were obtained with Balb/C mice and Sprague-Dawley rats (Figure 1b ).
Efficacy comparison of SP1017 with PVP
We compared SP1017 with PVP, another non-ionic polymer known to improve gene expression in muscle. 12 The low (10 kDa) and the high (40 kDa) molecular mass PVPs were used at the optimal concentration of 5% w/v as previously reported to formulate 5 and 50 g of pCMV-Luc before being injected into bilateral tibialis anterior muscles of 6-to 8-week-old female C57BL/6 mice. 12 The same doses of pCMV-Luc were formulated with 0.01% w/v SP1017. The luciferase assay was performed 7 days after injection. This study revealed ( Figure 1c ) that SP1017 was significantly more effective than the high molecular mass PVP. The low molecular weight PVP was able to increase gene expression significantly, but only when formulated with the high dose of DNA. Superfect and Lipofectin that were also tested in these experiments (data not shown) were found to inhibit luciferase expression.
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Time-course of gene expression of pCMV-Luc/SP1017
For a more detailed comparison of naked pCMV-Luc and pCMV-Luc/SP1017, the time-course experiment was carried out using the above-described model. It was found that the expression of pCMV-Luc/SP1017 was significantly higher than that of naked DNA (Figure 2 ). The expression of naked DNA reached a maximum at day 4 and then declined, while in the case of pCMVLuc/SP1017, the luciferase activity in muscle was increasing until day 7. The AUC for the period of 5 weeks for pCMV-Luc/SP1017 and naked DNA were 43290470 and 12677044 RLU/week/mg, respectively.
Effect of SP1017 on ␤-galactosidase gene expression in muscle
To analyze tissue distribution of gene expression following intramuscular plasmid DNA administration, we used the ␤-galactosidase gene (pCMV-␤gal). Five g of pCMV␤gal formulated with 0.01% w/v SP1017 (pCMV␤gal/SP1017) and the same dose of naked DNA were injected i.m. in C57BL/6 mice. The histology analysis demonstrated that the areas of positive X-gal staining were considerably larger in animals injected with pCMV␤gal/SP1017, than those in mice treated with naked DNA (Figure 3 ). This finding suggests that SP1017 promotes distribution of plasmid DNA across the tissue.
Effect of SP1017 on erythropoietin gene expression in muscle
To explore the possibility of using the SP1017 carrier to express secretory therapeutic genes, a series of experiments was carried out using the erythropoietin gene (pCMV-mEPO). The murine erythropoietin gene was chosen for these experiments because its physiological effects can be easily monitored by performing hematocrit measurements on blood samples obtained from the treated mice. As shown in Figure 4a , the hematocrits of mice injected with 10 g of pCMV-mEPO formulated with 0.01% w/v SP1017 (pCMV-mEPO/SP1017) rose from 45% ± 2 (untreated mice) to 58% ± 4. The hematocrits of mice injected with the same dose of naked pCMVmEPO were only slightly higher than those in the untreated animals. The hematocrits of mice treated with pCMV-mEPO/SP1017 were increasing during 21 days after injection and then remained unchanged until at least 50 days after injection. The increase in hematocrits in pCMV-mEPO/SP1017-treated mice correlated with an increase in mEPO levels in serum and muscle as detected by ELISA on day 7 after injection ( Figure 4b and c) . The animals treated with naked DNA also showed a small, but significant increase in the mEPO level in muscle, while in serum of these animals, the levels of mEPO remained below the sensitivity of the method. The results of dose escalation study showed that the hematocrits of mice treated with 50 g of pCMV-mEPO/SP1017 reached 73% ± 2, which is comparable to the level achievable with adeno-associated virus (Figure 4d ). 23 
Discussion
Intramuscular administration of plasmid DNA is a promising strategy to express therapeutic genes, however, it is limited by a relatively low level of gene expression. Commercially available cationic carriers, such as dendrimers (Superfect) and lipid-based systems (Lipofectin), known to improve gene expression in various tissues have demonstrated significant inhibitory effects in comparison with naked DNA. 24 We report here that a nonionic carrier, SP1017, comprising two amphiphilic block copolymers, pluronics L61 and F127, increases intramuscular gene expression by up to 10-fold. The potentiating effect of SP1017 has been demonstrated in mice and rats suggesting that it can be potentially used in humans. Compared with PVP, the only nonviral system described to be effective in intramuscular settings, a much lower concentration of the SP1017 carrier and at least 10 times less DNA are required to achieve a significant increase in gene expression and the related physiological response. This finding suggests that the use of SP1017 might overcome major drawbacks encountered with higher doses of DNA, such as induction of an undesirable immune response against the therapeutic gene, which can be potentiated by a higher dose of DNA containing CpG motifs, and provoking the development of autoimmune diseases, such as lupus, related to immune response to DNA. 15, [25] [26] [27] The muscle did not appear to be affected by SP1017 as observed in histology analysis, and the animals injected with SP1017 did not show any signs of discomfort. This is in contrast with electroporation that has been recently reported to be associated with the risk of extensive and irreversible muscle damage after electrical trauma. 16 The mechanism of action of SP1017 on gene transfer remains to be explored. The histology experiments with pCMV-␤gal/SP1017 (Figure 3) showed that the carrier significantly enhances DNA distribution through the tissue, by this way increasing its bioavailability. It is also possible that SP1017 affects DNA interaction with extracellular matrix and its cellular uptake. More detailed studies on this subject are in progress in this laboratory. The experiments in which DNA and SP1017 were administered separately (the carrier first and then DNA, and Gene Therapy vice versa) revealed that even at short intervals between the injections, the potency of SP1017 was considerably reduced (data not shown). This observation suggests that a complex between DNA and the carrier might exist to ensure the effect of SP1017. Unlike electrostatic complexes formed between DNA and cationic carriers that can be easily detected by various methods, such as gel retardation assay and ethidium displacement, the DNA/SP1017 complex is likely to be formed by weak interactions, such as hydrogen bonds between DNA and the poly(ethylene) oxide part of poloxamer, however, a more detailed study is required to draw a final conclusion. 12 One speculation can be made regarding the biochemical mechanism of SP1017 effect on DNA expression in muscle. We have previously demonstrated that lipophilic poloxamers dramatically increase membrane permeability and drug release from endosomes in multidrug-resistant (MDR) tissue phenotypes, such as drugresistant tumors, brain microvessel endothelium and small intestine epithelium. [28] [29] [30] [31] [32] All these tissues are known to express high levels of ATP-dependent transporters, such as P-glycoprotein, MRP and H + ATPase. 33 The increased ATPase activity in the above cells results in abnormally high pH gradients and is related to an enhanced tendency to phase transitions in the lipid membrane. 34 Our recent findings suggest that the selective effect of lipophilic poloxamers in MDR cells is related to these specific features. 35 The muscular tissues are also characterized by a high ATPase activity that is required for their normal functioning. 36 Therefore, the effect of SP1017 on DNA expression in muscles may be related to this similarity between MDR tissues and muscles. We have recently observed that SP1017 significantly increases DNA uptake into MDR cells that are normally poorly transfectable with both naked DNA and DNA complexed with cationic carriers (manuscript in preparation). This finding provides additional support to the above hypothesis.
Figure 4 (a) Hematocrits of mice injected with pCMV-mEPO/SP1017. Each tibialis anterior muscle of C57Bl/6 mice (6-to 8-week-old females) was injected with 50 l of the dosing solution containing 10 g of pCMV-mEPO formulated with SP1017 at 0.01% w/v. The blood samples were collected over a period of 50 days to perform the hematocrit measurements. (b) and (c) mEPO levels in serum and muscle extracts after intramuscular injection of pCMV-mEPO/SP1017. The mEPO levels were determined by ELISA in serum and muscle extracts 7 days after intramuscular injection (n
The intravenous toxicity studies performed on SP1017 in rodents and non-rodents showed that the maximal tolerable doses of this carrier were 1350 mg/kg (rats) and 1080 mg/kg (dogs) for acute toxicity, and 337 mg/kg/day (rats) and 225 mg/kg/day (dogs) -for subacute toxicity (14 daily injections). 22 These results, compared with the optimal SP1017 dose used in the experiments described here (0.25 mg/kg), indicate over a 1000-fold safety margin.
Poloxamers are listed in the US and British Pharmacopeia as inactive excipients and are widely used in a variety of clinical applications. We believe that the described system constitutes a simple and efficient gene transfer method applicable to multiple gene therapy protocols involving injection of plasmid DNA to achieve local or systemic production of therapeutic proteins.
Materials and methods

Plasmid DNAs
Plasmids encoding luciferase (pCMV-Luc, 7.2 kb) and ␤-galactosidase (pCMV-␤gal, 7.2 kb) both under control of the cytomegalovirus immediate-early region promoter and enhancer were used throughout the study. The murine erythropoietin gene was cloned by RT/PCR. Briefly, cDNA encoding mEPO was obtained by reverse transcription of mRNAs extracted from kidneys of mice treated for 3 days with phenylhydrazine. 37 The amplification was performed using the sense 5Ј-ATAA-CAAGCTTGGCGCGGAGATGGGGGTG and antisense 5Ј-ATAACTCTAGAACGGTGGCAGCAGCATGTCAC primers. The amplified erythropoietin gene was inserted into the XbaI and HindIII sites of pcDNA/Amp1.1 (Invitrogen, Carlsbad, CA, USA), and the sequence was confirmed by DNA sequencing. All plasmids were expanded in E. coli DH5␣ strain and prepared using a Qiagen Endotoxin-free plasmid Giga-prep kit according to the supplier's protocol (Qiagen, Mississauga, ON, Canada). The quantity and quality of the purified plasmid DNA was assessed by optical density at 260 and 280 nm and also by electrophoresis in 1% agarose gel. The purified plasmid DNA was resuspended in sterile saline (Gibco-BRL, Burlington, ON, Canada) and kept frozen in aliquots at a concentration of 5 mg/ml. Animals C57Bl/6 and Balb/C mice (6-to 8-week-old females) and Sprague-Dawley rats (3-month-old males) were used throughout this study. The animals were kept in groups of four and fed ad libitum. Before each intramuscular injection, the animals were anesthetized with a mixed solution of ketamine and xylazine.
Formulation of plasmid DNA with SP1017 The SP1017 solution for injections was manufactured by Supratek Pharma (Laval, QC, Canada). The same batch was used throughout the study. Briefly, equal volumes of plasmid DNAs and SP1017 (F127:L61 mixed at an 8 to 1% ratio) were gently mixed to get the required final concentrations of DNA per 50 l of saline 0.15 M and 0.01%.w/v of SP1017. The formulation was used immediately for i.m. injection but is stable for several months if stored at 4°C.
Intramuscular injection procedure
The animals were injected intramuscularly into tibialis anterior muscles with 50 l of plasmid DNA containing various amounts of different plasmids formulated with various amounts of SP1017. Five g of each pCMV-Luc and pCMV-␤gal, and 5, 10 and 50 g of pCMV-mEPO were respectively injected per tibialis anterior muscle. In the case of reporter genes, both left and right tibialis anterior muscles of the animals were injected to reduce the number of animals used in the study.
Luciferase assay
The mice were killed 24 h after intramuscular injection with the exception of time-course experiments, where the mice were killed at various time-points. Each injected muscle was dissected and rapidly homogenized with a Polytron in a cell lysis buffer (Promega Corporation, Madison, WI, USA). The extraction mixture was kept on ice for 30 min and then centrifuged at 13 000 g for 2 min. The supernatants were kept and analyzed for luciferase activity. The assay was performed as follows: 10 l of the supernatant were added to luminometric tubes containing 100 l of luciferase substrate (Promega Corporation). Light emission was measured with a luminometer (Berthold) for a period of 5 s. The data were reported in relative light units per second per muscle.
Histological processing and analysis C57Bl/6 mice (6-to 8-week-old females) were injected with 5 g of pCMV-␤gal formulated with 0.01% w/v of SP1017. The muscles were harvested 5 days after injection and processed for histology. To analyze the tissue expression of the ␤-galactosidase gene, 5 m frozen sections were cut on to glass slides and stained with an in situ ␤-galactosidase staining kit (Stratagene, La Jolla, CA, USA). The sections were then washed with PBS, counterstained lightly with eosin and mounted in glycerol for photography.
Erythropoietin
Five, 10 and 50 g of pCMV-mEPO were formulated with 50 l of 0.01% w/v SP1017 and injected intramuscularly into tibialis anterior muscles. The blood samples were collected over a period of 50 days to perform weekly hematocrit measurements. The levels of mEPO in serum and muscle were measured with a Quantikine IVD Erythtropoietin ELISA kit (R&D Systems, Minneapolis, MN, USA) and used according to the manufacturer's protocol.
Statistical analysis
The P values were obtained by means of the Student's t test following logarithmic transformation of the data in the case of luciferase experiments. Each P value corresponded to the comparison of naked DNA versus DNA/SP1017 for each individual day. The P values were also confirmed in the Mann-Whitney test for luciferase data.
